Evidence map›Paper›PMID 25547711›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015

A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.

Amit Etkin, Brian Patenaude, Yun Ju C Song, Timothy Usherwood, William Rekshan, Alan F Schatzberg, A John Rush, Leanne M Williams

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04839822 (Efficacy of the Digital Self-help Programme Edupression.Com® Evaluated Within a Randomized Controlled Trial in Mild to Moderate Unipolar Depressive Patients), which is not on this map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04839822 nacompletednot on this mapstarted 2021, after this paper: background citation

Efficacy of the Digital Self-help Programme Edupression.Com® Evaluated Within a Randomized Controlled Trial in Mild to Moderate Unipolar Depressive Patients

TypeinterventionalSponsorMedical University of ViennaRan2021 to 2023Enrolled250ConditionsDepressive, Episode, Major, Recurrent Depressive Disorder, Current Episode Moderate, Recurrent Depressive Disorder, Current Episode MildArmsedupression.com®, Health tips, Surveys, Popular psychological interventions
3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amit Etkin1] Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA [2] Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Brian Patenaude1] Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA [2] Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Yun Ju C SongBrain Dynamics Center, University of Sydney Medical School and Westmead Millennium Institute for Medical Research at Westmead Hospital, Sydney, NSW, Australia.
Timothy UsherwoodDepartment of General Practice, Sydney Medical School, Westmead, University of Sydney, Sydney, NSW, Australia.
William Rekshan1] Brain Resource, Sydney, NSW, Australia [2] Brain Resource, San Francisco, CA, USA.
Alan F SchatzbergDepartment of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
A John RushDuke-National University of Singapore, Singapore, Singapore.
Leanne M Williams1] Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA [2] Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC) Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA [3] Brain Dynamics Center, University of Sydney Medical School and Westmead Millennium Institute for Medical Research at Westmead Hospital, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression involves impairments in a range of cognitive and emotional capacities. It is unknown whether these functions can inform medication choice when considered as a composite predictive biomarker. We tested whether behavioral tests, grounded in the neurobiology of cognitive and emotional functions, predict outcome with common antidepressants. Medication-free outpatients with nonpsychotic major depressive disorder (N=1008; 665 completers) were assessed before treatment using 13 computerized tests of psychomotor, executive, memory-attention, processing speed, inhibitory, and emotional functions. Matched healthy controls (N=336) provided a normative reference sample for test performance. Depressed participants were then randomized to escitalopram, sertraline, or venlafaxine-extended release, and were assessed using the 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR16) and the 17-item Hamilton Rating Scale for Depression. Given the heterogeneity of depression, analyses were furthermore stratified by pretreatment performance. We then used pattern classification with cross-validation to determine individual patient-level composite predictive biomarkers of antidepressant outcome based on test performance. A subgroup of depressed participants (approximately one-quarter of patients) were found to be impaired across most cognitive tests relative to the healthy norm, from which they could be discriminated with 91% accuracy. These patients with generally impaired cognitive task performance had poorer treatment outcomes. For this impaired subgroup, task performance furthermore predicted remission on the QIDS-SR16 at 72% accuracy specifically following treatment with escitalopram but not the other medications. Therefore, tests of cognitive and emotional functions can form a clinically meaningful composite biomarker that may help drive general treatment outcome prediction for optimal treatment selection in depression, particularly for escitalopram.

Indexed as

Psychological TestsAdolescentAdultAgedAntidepressive AgentsCitalopramCognitionComputersDelayed-Action PreparationsEmotionsFemaleHumansMajor Depressive DisorderMaleMiddle AgedPrognosisAntidepressive AgentsCitalopramDelayed-Action PreparationsSertralineVenlafaxine Hydrochloride

Identifiers

PMID25547711
PMCPMC4397406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.